Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Taxes (2024 - 2026)

Kura Oncology has reported Current Taxes over the past 3 years, most recently at $239000.0 for Q1 2026.

  • Quarterly Current Taxes fell 89.55% to $239000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $239000.0 through Mar 2026, down 89.55% year-over-year, with the annual reading at $239000.0 for FY2025, 88.4% down from the prior year.
  • Current Taxes was $239000.0 for Q1 2026 at Kura Oncology, roughly flat from $239000.0 in the prior quarter.
  • Over five years, Current Taxes peaked at $2.3 million in Q1 2025 and troughed at $239000.0 in Q4 2025.
  • The 3-year median for Current Taxes is $1.2 million (2024), against an average of $1.2 million.
  • Year-over-year, Current Taxes crashed 88.4% in 2025 and then plummeted 89.55% in 2026.
  • A 3-year view of Current Taxes shows it stood at $2.1 million in 2024, then crashed by 88.4% to $239000.0 in 2025, then changed by 0.0% to $239000.0 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Current Taxes are $239000.0 (Q1 2026), $239000.0 (Q4 2025), and $2.3 million (Q1 2025).